Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014

Publish Date:- Aug-2014       No Of Pages (556)

Electronic Access - Single User License $2000 Buy Now
CD-ROM Mail Delivery $2400Buy Now
Hard Copy Mail Delivery $3000 Buy Now
Electronic Access - Multi-User License $4000 Buy Now


The conventional methods developed to prevent and eradicate the prevalence of cancer have achieved limited success in cancer treatment. These methods are confined to low specificity, safety and large number of side effects, which prompted the researchers to look for a better solution. It has been discovered that peptides can be used for effective and viable treatment of cancer without having disadvantages of conventional methods. The quintessential for using peptide cancer therapeutics is that they have high specificity, safety and efficacy which is not provide by therapeutics available in market.

The completion of human genome sequencing has helped in the research and development of peptide cancer therapeutics. The data allowed the researchers to look deep into the root cause of cancer hidden in human genome. This has allowed targeting cancer cells with high accuracy; thus, increasing the probability of treatment with high success rates. Using this data several novel molecules are being developed, which will have higher stability, effective delivery and minimal or no side-effects.

Peptide cancer therapeutics has edge in treating rare type of cancers. Conventional approaches of cancer treatments are unable to treat them successfully. Sometimes these approaches cannot be used due to unspecificity or they are not effective at all. For instance, brain cancer is a rare type of cancer that falls in this category. Brain is a very sensitive organ, to protect itself from unwanted substances it has developed blood brain barrier. It very difficult to breach, here conventional cancer therapeutics faces a sever challenge. On the other hand, peptide cancer therapeutics is able to overcome this barrier. Markets for these medicines have a huge potential and many medicines are under various phases of clinical trials

Peptide cancer therapies hold a promising future for the treatment of cancer. Various clinical trials studies have demonstrated the fact that the potential of peptide based drugs to prevent and eradicate cancer is far effective than conventional cancer therapy. In some studies, it has been found that combinatorial therapies will be more effective than individual methods. In combinatorial therapy, both conventional and peptide based cancer therapeutics are used for the treatment.


Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014” Report Highlight:

• Mechanism & Market Overview of Peptide Cancer Therapeutics
• Clinical Pipeline by Analysis Phase, Indication, Company & Country
• Peptide Cancer Drugs in Pipeline: 183 Drugs
• Marketed Peptide Cancer Drugs: 20 Drugs
• Majority Drugs in Preclinical Phase: 75 Drugs
• Suspended & Discontinued Peptide Cancer Drugs: 143 Drugs
• Peptide Cancer Therapeutics Market Future Growth Prospects


The conventional methods developed to prevent and eradicate the prevalence of cancer have achieved limited success in cancer treatment. These methods are confined to low specificity, safety and large number of side effects, which prompted the researchers to look for a better solution. It has been discovered that peptides can be used for effective and viable treatment of cancer without having disadvantages of conventional methods. The quintessential for using peptide cancer therapeutics is that they have high specificity, safety and efficacy which is not provide by therapeutics available in market.

The completion of human genome sequencing has helped in the research and development of peptide cancer therapeutics. The data allowed the researchers to look deep into the root cause of cancer hidden in human genome. This has allowed targeting cancer cells with high accuracy; thus, increasing the probability of treatment with high success rates. Using this data several novel molecules are being developed, which will have higher stability, effective delivery and minimal or no side-effects.

Peptide cancer therapeutics has edge in treating rare type of cancers. Conventional approaches of cancer treatments are unable to treat them successfully. Sometimes these approaches cannot be used due to unspecificity or they are not effective at all. For instance, brain cancer is a rare type of cancer that falls in this category. Brain is a very sensitive organ, to protect itself from unwanted substances it has developed blood brain barrier. It very difficult to breach, here conventional cancer therapeutics faces a sever challenge. On the other hand, peptide cancer therapeutics is able to overcome this barrier. Markets for these medicines have a huge potential and many medicines are under various phases of clinical trials

Peptide cancer therapies hold a promising future for the treatment of cancer. Various clinical trials studies have demonstrated the fact that the potential of peptide based drugs to prevent and eradicate cancer is far effective than conventional cancer therapy. In some studies, it has been found that combinatorial therapies will be more effective than individual methods. In combinatorial therapy, both conventional and peptide based cancer therapeutics are used for the treatment.


Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014” Report Highlight:

• Mechanism & Market Overview of Peptide Cancer Therapeutics
• Clinical Pipeline by Analysis Phase, Indication, Company & Country
• Peptide Cancer Drugs in Pipeline: 183 Drugs
• Marketed Peptide Cancer Drugs: 20 Drugs
• Majority Drugs in Preclinical Phase: 75 Drugs
• Suspended & Discontinued Peptide Cancer Drugs: 143 Drugs
• Peptide Cancer Therapeutics Market Future Growth Prospects

1. Introduction to Peptide Cancer Therapeutics

2. Mechanism of Peptide Cancer Therapeutics

3. Peptide Cancer Therapeutics Market Outlook
  3.1 Market Overview
  3.2 Cancer Peptide Clinical Pipeline Overview

4. Peptide Cancer Therapeutics Market Dynamics
  4.1 Favorable Growth Parameters
  4.2 Key Issues to be Resolved

5. Peptide Cancer Therapeutics Market Future Growth Prospects

6. Peptide Cancer Drug Clinical Pipeline by Phase, Indication, Company & Country
  6.1 Research
  6.2 Preclinical
  6.3 Clinical
  6.4 Phase-0
  6.5 Phase-I
  6.6 Phase-I/II
  6.7 Phase-II
  6.8 Phase-III


7. Marketed Peptide Cancer Drug Insight by Indication, Country & Company

8. Suspended & Discontinued Peptide Cancer Drug in Clinical Trial by Phase, Indication, Company & Country

  8.1 No Development Reported
  8.2 Discontinued
  8.3 Market Withdrawal
  8.4 Suspended

9. Competitive Landscape
  9.1 AngioChem
  9.2 Antigen Express
  9.3 Amgen
  9.4 GlaxoSmithKline
  9.5 Galena Biopharma
  9.6 Ipsen
  9.7 Merck & Co
  9.8 PeptiDream
  9.9 Roche
  9.10 Sanofi


List of Figures

Figure 1-1: Use of Peptides in Various Ailments
Figure 2-1: Mode of Action of Peptide Cancer Therapeutics
Figure 2-2: Targeted Peptide Cancer Therapeutics Development
Figure 3-1: Global Peptide Market (US$ Billion), 2013-2018
Figure 3-2: Global Peptide Cancer Drug Pipeline by Phase (%), 2014
Figure 3-3: Global Peptide Cancer Drug Pipeline by Phase (Number), 2014
Figure 3-4: No Development Reported in Peptide Cancer Drug Pipeline by Phase (%), 2014
Figure 3-5: No Development Reported in Peptide Cancer Drug Pipeline by Phase (Number), 2014
Figure 3-6: Discontinued Peptide Cancer Drug Pipeline by Phase (%), 2014
Figure 3-7: Discontinued Peptide Cancer Drug Pipeline by Phase (Number), 2014
Figure 3-8: Suspended Peptide Cancer Drug Pipeline by Phase (%), 2014
Figure 3-9: Suspended Peptide Cancer Drug Pipeline by Phase (Number), 2014